Page last updated: 2024-09-03

mk 0663 and Hemorrhagic Thrombocythemia

mk 0663 has been researched along with Hemorrhagic Thrombocythemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ciabattoni, G; Davì, G; Dragani, A; Ferrante, E; Habib, A; Lattanzio, S; Mattoscio, D; Mucci, L; Pascale, S; Patrono, C; Petrucci, G; Ranelletti, FO; Recchiuti, A; Rocca, B	1

Trials

1 trial(s) available for mk 0663 and Hemorrhagic Thrombocythemia

Article	Year
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood, 2010, Feb-04, Volume: 115, Issue:5 Topics: Adult; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Etoricoxib; Female; Humans; Immunohistochemistry; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Sulfones; Thrombocythemia, Essential; Thromboxane A2; Thromboxane B2; Thromboxanes; Treatment Outcome	2010

Article

Year

The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.

Blood, 2010, Feb-04, Volume: 115, Issue:5

Topics: Adult; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Etoricoxib; Female; Humans; Immunohistochemistry; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Sulfones; Thrombocythemia, Essential; Thromboxane A2; Thromboxane B2; Thromboxanes; Treatment Outcome

2010